Last updated: April 28, 2026
What is the current clinical-trials status for griseofulvin?
No ongoing, clearly identifiable late-stage registrational studies were found for griseofulvin in major public trial registries at the time of this update. Griseofulvin is an established antifungal with long market history and older regulatory use patterns; recent literature and filings largely center on formulation and regional approvals rather than new Phase 3 development.
Where griseofulvin development concentrates
Clinical activity for griseofulvin (when it appears in public sources) tends to be:
- Bioequivalence and formulation studies (e.g., tablet versus suspension; particle size and solubility work)
- Small-scale efficacy/safety studies in targeted populations (often pediatric dosing studies in specific regions)
- Registry-and-observation type studies, where endpoints are clinical cure and tolerability
Implication for investors and R&D: The pipeline profile is primarily life-cycle management rather than platform-style innovation. Commercial differentiation typically comes from pediatric formulations, improved exposure, and access (cost and supply), not new mechanism or new indications.
Source basis: Trial activity and lifecycle patterns are consistent with the absence of prominent recent Phase 3 registrational programs in major trial listings for this drug. Clinical trial registry indexing and public searches were used as the basis for this status call.
What is griseofulvin’s market structure today?
Griseofulvin is an oral systemic antifungal used for dermatophyte (tinea) infections, including:
- Tinea capitis (scalp ringworm), a key pediatric use case
- Onychomycosis (nail fungal infections) where systemic therapy is selected
- Tinea corporis/cruris in select cases, generally when topical therapy is insufficient
Commercial reality: generics dominate
Griseofulvin is off-patent in most markets, and pricing is driven by:
- Generic entry depth and buyer contracting
- Formulation mix (tablet versus suspension where available)
- National guideline adoption and reimbursement practices
- Pediatric willingness-to-use (suspension acceptance is a commercial lever)
Demand drivers
The market is supported by:
- Persistent incidence of dermatophyte infections
- Pediatric treatment need (tinea capitis)
- Recurrent infection patterns in community settings
- Global access programs and national tendering
Competitive landscape
Competition is predominantly:
- Generic manufacturers (multiple suppliers per major geography)
- Regional formulation leaders (where specific strengths and pediatric presentations dominate)
Source basis: Market structure is consistent with griseofulvin’s long commercial history and generic penetration described in regulatory and reference compendia.
How big is the griseofulvin opportunity and what will it do next?
A single authoritative global market size figure is not consistently available in the public domain for this drug due to:
- Broad inclusion within “systemic antifungals”
- Generic interchangeability and fragmented reporting
- Differences in whether onychomycosis is counted in-country formularies and payer views
Given that, the most decision-relevant approach for projection is to model the drug’s demand through incidence and treatment penetration using conservative, scenario-based logic. The resulting view is that griseofulvin remains a stable, low-to-mid single-digit value-growth category tied to:
- Mild population growth in endemic settings
- Switching to systemic therapy during guideline updates
- Gradual price compression mitigated by formulation premiums
Projection framework (practical for business planning)
Base-year sales trend assumption (value)
- Flat to modest growth driven by volume stability and tender replenishment cycles
- Limited price expansion due to generic competition
- Growth is more likely to show up in countries and segments with pediatric or suspension availability
Base-year sales trend assumption (volume)
- Stable to slight growth where burden is consistent and access expands
3-scenario market outlook (global, indicative)
This outlook is designed for planning range rather than point-estimate precision:
| Scenario (Global) |
What it implies |
Annual value growth (indicative) |
3-year direction |
| Downside |
Continued price erosion, supply volatility in select markets, slower systemic uptake |
-2% to 0% |
Flat to slight decline |
| Base case |
Stable reimbursement, continued generic competition without major supply shocks |
0% to 3% |
Low growth |
| Upside |
Expanded access for pediatric formulations and better guideline adherence |
3% to 6% |
Steady growth |
Investment read: Griseofulvin is not positioned for high-rate growth. The highest upside tends to come from formulation economics, supply security, and channel access rather than clinical innovation.
Where can clinical updates create commercial value for griseofulvin?
Even with minimal registrational pipeline activity, clinical updates can move commercial outcomes through:
- Label clarifications that tighten dosing for pediatric populations
- Evidence that supports improved exposure (bioavailability) and tolerability
- Local guideline updates that specify systemic therapy when topical options fail
Value levers in development
The most common high-ROI development paths for griseofulvin are:
- Pediatric-optimized suspension formulations that improve adherence
- Exposure-enhancing formulations that reduce treatment failures from sub-therapeutic exposure
- Strength and dosing convenience that improves prescriber uptake
Evidence anchors used for lifecycle decisions
The drug’s core clinical foundation is established antifungal efficacy against dermatophytes:
- Systemic therapy is standard for tinea capitis, especially in children
- Treatment course duration is guideline-dependent and often multi-week
- Liver metabolism and drug interaction management is part of routine prescribing
Source basis: Dosing and safety management are summarized in major prescribing references and antifungal clinical guidance.
What safety and regulatory themes affect market continuity?
Clinical and regulatory attention for griseofulvin usually centers on:
- Hepatic safety monitoring practices
- Drug interaction risk through hepatic metabolism
- Tolerability and adherence, especially in pediatric settings
- Adherence to course length to avoid relapse and resistance selection pressure on local pathogens
These factors influence:
- Prescriber comfort
- Formulary inclusion
- Payer restrictions and monitoring requirements
How does griseofulvin compare with systemic antifungal alternatives?
Griseofulvin competes within a systemic antifungal class that includes other oral agents used for dermatophyte and nail infections, where selection depends on:
- Infection site (scalp versus nail)
- Pathogen and region
- Duration of therapy tolerance
- Drug interaction burden and hepatic monitoring requirements
- Coverage and pricing
Practical positioning
- For tinea capitis, oral systemic therapy is usually preferred for confirmed cases, and griseofulvin is often the reference systemic option in many formularies.
- For onychomycosis, payer and clinician preference often shifts toward other systemic therapies depending on local pricing and tolerability data; this can cap griseofulvin value growth in some markets.
What is the investment-grade outlook for griseofulvin supply and demand?
Griseofulvin’s investment outlook is anchored to:
- Tender cycles and generic contracting dynamics
- Pediatric formulation supply and consistent availability
- Ongoing guideline usage for scalp dermatophyte infections
- Regulatory maintenance and bioequivalence competitiveness
Key watch items
- Manufacturing continuity: supply disruptions can temporarily lift pricing and stabilize revenue for surviving SKUs.
- Pediatric formulation availability: suspension access drives sustained prescribing in children.
- Formulary rules: monitoring requirements and payer restrictions influence patient reach.
- Generic price compression: the dominant long-run pressure on value growth.
Clinical trials: which endpoints matter most for griseofulvin lifecycle studies?
For lifecycle studies and bioequivalence programs, the most common endpoint patterns are:
- Pharmacokinetics (Cmax, Tmax, AUC) and bioavailability alignment
- Safety/tolerability over short exposure windows
- Clinical response rates for dermatophyte infections in smaller efficacy studies
- Clinical cure versus mycological cure definitions (region-dependent)
These endpoints matter because they affect:
- Bioequivalence approvals and switchability
- Prescriber confidence in interchangeability
- Patient adherence and real-world treatment completion
Key Takeaways
- Griseofulvin’s public clinical-trials footprint is dominated by lifecycle and formulation activity rather than new late-stage registrational programs.
- The market is generics-led; growth is constrained by price compression and driven by access and formulation mix.
- A business-planning projection points to stable demand with low single-digit value growth in a base case, and flat-to-negative value outcomes in downside scenarios.
- Commercial upside is most likely to come from pediatric formulation supply, dosing convenience, and execution in tender and formulary channels.
FAQs
1) Is griseofulvin currently undergoing major Phase 3 trials?
No major registrational Phase 3 programs are evident in public trial listings at this update level.
2) What indications drive griseofulvin demand most?
Tinea capitis is the highest-consistency systemic driver, supported by pediatric prescribing patterns.
3) Why does market growth look limited for griseofulvin?
Generics dominate and pricing is pressured by competition, limiting value expansion.
4) What development types create the most commercial impact for off-patent griseofulvin?
Bioequivalence and pediatric-focused formulation improvements that reduce adherence barriers and support consistent prescribing.
5) What are the key risk factors for ongoing sales?
Supply continuity, payer monitoring requirements, and continued price erosion.
References
[1] U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots and related review materials for griseofulvin. FDA. https://www.fda.gov
[2] National Library of Medicine. (n.d.). ClinicalTrials.gov search results for griseofulvin. ClinicalTrials.gov. https://clinicaltrials.gov
[3] European Medicines Agency. (n.d.). EPAR and related regulatory information for griseofulvin products. EMA. https://www.ema.europa.eu
[4] United States Pharmacopeia / prescribing reference compendia entries on griseofulvin dosing, safety, and drug interactions (latest available).
